What's on the Horizon in Atopic Dermatitis? A Focus on OX40-OX40 Ligand-Targeted Therapies

episode

Keeping Current CME not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Oil Rises on Iran Tensions, US-China Tariffs Cut List, More 7 min · 28 Sep 2026 · Bloomberg News Now

1216: United States wins the 2026 Presidents Cup 1h 58m · 28 Sep 2026 · No Laying Up - Golf Podcast

NPR News: 09-27-2026 10PM EDT 5 min · 28 Sep 2026 · NPR News Now

Hormuz Stalemate, US-China Agree to Reciprocal Tariff Cuts, More 7 min · 28 Sep 2026 · Bloomberg News Now

10PM ET 09/27/2026 Newscast 3 min · 28 Sep 2026 · Fox News Hourly Update

Banished: the secret Trump deals sending migrants across the world 30 min · 28 Sep 2026 · Today in Focus

Report any issue

Source

Recorded26 Jun 2024

Publisherkeepingcurrentcme.libsyn.com ↗

Handlerec:4299696

Show notes

Did you know that targeting the OX40-OX40 ligand (OX40-OX40L) pathway may lead to long-term remission in atopic dermatitis (AD)? Credit available for this activity expires: 6/26/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001214?ecd=bdc_podcast_libsyn_mscpedu

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in